KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC
December 21st 2023Experts discuss the difference in toxicities demonstrated in both adagrasib and sotorasib in second line KRAS-mutated NSCLC, highlighting hepatotoxicity and achieving durable response with combination PD-1/PD-L1 inhibitors.
Read More
CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC
December 21st 2023Dr. Sabari and Dr. Garon discuss second line sotorasib and the results of the CodeBreaK 200 study, highlighting the recent FDA oncologic drugs advisory committee (ODAC) and their assessment of the study results.
Read More
Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition
December 14th 2023A comprehensive review of hepatotoxicity in ongoing studies evaluating KRAS inhibitors in the frontline setting, highlighting adagrasib and sotorasib in the KRYSTAL-7 and CodeBreaK 100 studies, respectively.
Read More
The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC
December 7th 2023Joshua K. Sabari, MD, and Edward B. Garon, MD, MS, discuss the role and potential impact of KRAS G12C inhibitors in the frontline setting, highlighting the potential of monotherapy and in combination with a PD-1/PD-L1 inhibitor.
Read More
Dr. Sabari on the EVOKE-02 Trial With Sacituzumab Govitecan in NSCLC
November 14th 2023Joshua K. Sabari, MD, discusses the ongoing phase 2 EVOKE-2 trial investigating sacituzumab govitecan-hziy in non– small cell lung cancer; emerging data on antibody-drug conjugates in the second– or first-line treatment setting; and the planned phase 3 EVOKE-03 trial of sacituzumab govitecan plus pembrolizumab as a frontline treatment.
Read More